Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07352969 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Not Yet Recruiting → Active, Not Recruiting Start date changed from estimate of Feb 6, 2026 to Feb 5, 2026 · Eligibility criteria expanded, about 17 words · Site contact updated Show 3 more changesShow less
    • Start date changed from estimate of Feb 6, 2026 to Feb 5, 2026
    • Eligibility criteria expanded, about 17 words
    • Site contact updated
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension
Trial Details
NCT Number NCT07352969
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Hypertension
Enrollment 352 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov